Thank you!
We will contact you shortly
- EN
- RU
FOUNDING SUPPORTER CAMPAIGN
Your chance to shape the future — humanity's in general, and your own in particular
We are opening a door for you — into a promising scientific development that may hold the key to a significantly longer, healthier, and more active life. For people in general. And for you personally.
Take part, and you help put a technology for staying healthy and highly capable for decades to the scientific test — and you are the first to see the results, and the first to use it.
THE GAP
You've measured. Now what?
You can quantify your health better than any generation before you: blood panels, wearables, a whole arithmetic of scores and indices. Here is the catch. Measured, assessed — and then what? The numbers tell you what is happening to you. With the years, what is happening pleases you less and less. What the numbers will never tell you is what to do about it. That leaves three options: resign yourself to a fairly standard age-related decline, invent a practical answer of your own — or take one that has already been worked out and tested.
Chronic low-grade systemic inflammation — inflammageing — is present in a large share of adults as they age. It is one of the main drivers of biological ageing and of the systemic diseases that follow: cardiovascular disease, type 2 diabetes, dementia, cancer and frailty. Metabolic function declines alongside it.
Blood tests can detect it. What to do about it is far less clear.
The changes start early. Muscle mass, aerobic capacity and insulin sensitivity begin a slow, measurable decline from the mid-thirties — long before anything is felt.
Metabolic health
Inflammageing links ageing to insulin resistance, metabolic syndrome, type 2 diabetes and kidney disease. Acting on this process early is a well-founded opportunity for healthier ageing.
Cardiovascular health
Chronic low-grade systemic inflammation and metabolic dysfunction are key risk factors for the heart and blood vessels — and their role only grows with the years.
Energy, strength & resilience
Beyond disease, chronic systemic inflammation can feed everyday fatigue, pain and weakness — gradually eroding quality of life.
WHAT WE BUILD
Measure. Act. Verify the result. Adjust — and move up a level.
And this is where an opportunity opens up for you.
We are developing an objective index of your current state and a targeted physical activity programme that works on the principle of adaptive systemic optimisation. It is designed to act in exactly the proportions and directions that one particular person needs — given that person's own balance of health parameters. Or ill-health.
The general principle is simple: measure and assess — act — verify the result and adjust the programme — and carry on. Joining the programme, you get an objective assessment of where your health actually stands, go through a programme of targeted physical activity adapted to you, and after a set period assess the result. You then gain access to the next level of the programme, and the cycle continues for as long as you like — to optimise and maintain your health and functionality.
THE PROGRAMME · ADULTS 35+
Healthy Longevity
For anyone who values quality of life — today and for years to come
A gentle, progressive programme built on an easy-to-follow set of targeted exercises, performed to a set sequence with a precisely defined breathing pattern.
It is designed to support everyday function, metabolic health and healthy longevity. No fitness background is needed.
For the programme to reach a wide audience, one thing is needed: objective data on how well it works — and that is what the study is for.
The programme is built on two targeted mechanisms: a set of targeted exercises and a specially regulated breathing pattern, both focused on the abdominal region. The task is to act on the so-called gut barrier, whose increased permeability is a likely source of chronic low-grade systemic inflammation. In addition, the sustained, gentle load mainly recruits slow-twitch type 1 muscle fibres — the most insulin-sensitive, and therefore central to systemic metabolism. So the programme is aimed not only at the gut barrier, but also at a plausible route to better metabolic health overall.
THE SCORE
The Vitality capacity score
One number to steer by
Vitality capacity — the body's reserve of vitality — is a scientific term for the whole-system physiological reserve. As it runs down, the age-related decline in health, energy, activity and function sets in. The concept of vitality capacity was proposed by a WHO working group.
On that foundation we are building the vitality capacity score — a computed measure that draws your scattered laboratory and physical measurements of many parameters into one whole; how you feel is recorded separately and read alongside the score, never blended into it. The result is a clear overall picture of your state — a score from 0 to 100.It is built to establish where you start relative to the optimum for your age, and to track change.The programme is then tuned to you on that basis — and the positive shifts are tracked.
SCIENTIFIC EVIDENCE
What we already know
We have already run two clinical studies in two quite DIFFERENT, but equally serious diseases with chronic inflammation at their root: inflammatory bowel disease and fibromyalgia. In both cases the same targeted approach gave equally encouraging results.That is the principle of adaptive systemic optimisation at work: one and the same method, producing results for different people with different balances of health parameters.
Inflammatory bowel disease
Published in the peer-reviewed Journal of Science and Medicine in Sport, December 2025.
The targeted programme produced an encouraging signal in people with inflammatory bowel disease. In a four-week randomised, double-blind study of 26 patients, the targeted exercises were compared with general physical activity — not with rest. Both groups improved. In the small Crohn's disease subgroup of 15 people, 75% reached clinical remission with the targeted programme, versus 14% with general activity. And a stool marker of gut inflammation stayed stable with the targeted programme, while in the comparison group it rose.
Read the published study →
Fibromyalgia
Presented at the 15th International Congress on Autoimmunity, Prague, May 2026.
In patients with fibromyalgia, most people on the programme reached a clinically meaningful reduction in pain. The study was small and non-randomised: 30 patients, 15 on the programme and 15 continuing their usual lifestyle. 73% of the programme group met the pain-reduction threshold set in advance, versus 13% in the comparison group. Pain, fatigue and overall symptom burden also improved, and several gut-barrier and microbiome measures shifted toward a healthy profile. Some results held up under stricter statistical testing; others remain early signals that need confirmation. Manuscripts in preparation.
THE STUDY
The study your participation makes possible
€40,000 budget · 50 participants aged 40–65 · 12 weeks · randomised design · inflammation + metabolism + wellbeing, measured before and after · results published openly
For our technology to be adopted widely and become the property of many rather than of a narrow circle, it needs serious scientific validation.
We know how to do it: we have access to all the laboratory and clinical resources required.
All that scientific validation of the method still needs is the funding that lets us put those resources to work and secure the next stage — a full test of the programme in generally healthy adults aged 40–65. With, of course, a scrupulous, objective assessment of the actual changes in metabolic markers and in the markers of chronic low-grade systemic inflammation — before and after.
The results of the study will be published openly.
Where the €40,000 goes
Every euro of the target goes to running the study and publishing the results.
Every euro above it goes to building the platform and bringing early access forward.
Payment processing fees and the cost of delivering your rewards are paid by ILT from its own funds — nothing is taken out of this budget for them.
Above €40,000. The campaign runs its full 33 days whatever the total. Every euro above the study budget goes to building the platform toward launch — setting up the delivery platform, producing the guided programme content, implementing the first version of the vitality capacity score, and onboarding supporters into early access.In plain terms: the more the campaign raises beyond the study, the sooner every supporter gets early access.
Why this study matters
We have working results indicating that this technology can be applied wherever a systemic optimisation of health is needed — specifically in an adaptive form.
But working results are not yet scientific proof. For the programme to reach a wide audience, one thing is needed: objective data on how well it works. The study runs the same cycle as the programme itself: measure and assess — act — verify the result.
The protocol is written, the team is in place, the laboratories are ready.
And right now is when you have the chance to become part of the process.
A NOTE FROM THE FOUNDERS
Why we are asking our community
We know the method works, because for many years we have seen the results and the effectiveness — for ourselves, and for a close circle of like-minded people. Now you know it too, because we have told you. But "we know" and "scientifically confirmed" are different things, and the distance between them is covered only by a study.
We could have sold first and looked for the evidence later — that is how almost the whole industry works. We prefer the other way round: scientific evidence first, product second.That is why we are inviting you to become part of this stage — and to be among the first to see the results and to use the programme.
Yuri Ostrinski & Andrii Siderskyi
THE TEAM
Science- and experience-led leadership
Yuri Ostrinski
FOUNDER & CEO
More than 25 years in healthcare, research and international projects. Originator of the ILT concept. Responsible for bringing the research, the partnerships and the company together.
Andrii Siderskyi
CO-FOUNDER · METHODOLOGY DIRECTOR
An internationally recognised expert in structured physical activity with more than 40 years of experience. Leads the design and development of ILT's targeted programmes.
Prof. Yehuda Shoenfeld
SCIENTIFIC ADVISOR
A globally recognised immunologist and authority on inflammation and immune-mediated disease. Advises ILT on its scientific framework, biomarkers and research validation.
SUPPORT TIERS
Become a founding supporter
It is simple. You choose a level — from €50. Your contribution runs the study; you receive what the first to arrive are entitled to: early access to the programme and the score before public launch, the founding price of €19 a month (the planned launch price is €25), and, if you wish, your name on the Wall of Founders. This is neither a donation nor an investment. You are not buying a share in the company and not giving to charity. You are becoming one of the first — and getting access before everyone else.
Prefer a different amount? Every contribution helps — write to us and we will arrange it.
All amounts are in euro. Premium membership is planned to launch at €25 per month; supporters at €100 and above keep the founding price of €19 per month, subject to the Campaign Terms. Prepaid membership months under every tier — including the one month at €50 — begin at public launch and can be activated at any time within 12 months of launch; early access before launch does not use them. “Lifetime” means for as long as the platform operates. The in-person launch workshop will be announced in advance; travel and accommodation are not included. The Founding Advisory Circle is a user-feedback group with no role in study design, analysis or reporting and no governance function; final product decisions rest with ILT. Payments are handled securely by Stripe. This is a founding-supporter campaign — you receive rewards (membership and, from €100, early access), not equity or a financial return. By contributing you accept the Campaign Terms (version 1.1, effective 9 October 2026). You may withdraw within 14 days of contributing — a model form is in Annex B of the Terms. ILT is not VAT-registered; no VAT is charged.
GOOD TO KNOW
Terms and common questions
How does this campaign work?
You contribute before the platform launches and receive the rewards attached to your chosen tier — access and terms that will not be offered again. The first funding priority is the study; funds above its €40,000 budget go to platform development. This is reward-based crowdfunding — not an investment, and not a charitable donation. We could have sold the programme first and looked for the evidence afterwards; that is how most of the wellness industry works. We do it the other way round: study first, product second. Your contribution funds the study; early access and the founding price are your side of the arrangement.
What exactly does my support pay for?
The pilot study and the evidence that comes out of it — laboratory work, running the programme, analysis, the first testing of the vitality capacity score, the preprint and the journal submission. The full budget is set out above.
What happens if you do not reach €40,000?
Both figures mean total secured study funding, including ILT's own €3,200. At €25,000 we can run a reduced study — a smaller group and the core blood panel — subject to final statistical and ethics review. Between €25,000 and €40,000, we add participants and markers as funding allows.Below €25,000 we will not begin recruitment. Every supporter will be offered a full refund, or the choice to leave their contribution in place while we secure the rest.
What happens if you raise more than €40,000?
The campaign does not close early — it runs to 10 November whatever the total. Funds above the €40,000 study budget go to building the platform toward launch: the delivery platform, the guided programme content, the first version of the vitality capacity score, and early-access onboarding. That is the part of our plan that most directly benefits supporters, because it brings early access forward for everyone. If we pass the target, we will report how these funds are used in the monthly updates. Contributions above the target carry the same rewards and the same terms as every other contribution.
What if the study does not show what you hope?
We publish it anyway. Sharing the results openly and submitting them to a journal are commitments to report what we find, not what we would prefer to find. And a result that falls short of our hopes is not a dead end — it is precisely the kind of data that shows where the method needs to grow, and the next version is built on it. Whatever the results, you will be the first to receive them — together with what we intend to do next.
Has the study been approved by an ethics committee?
Not yet. The ethics application is in preparation, and no participant will be recruited until approval is granted. Funding the campaign is what allows that process to move forward.
Can I take part in the study?
No. Taking part in the campaign does not give access to the study, and places cannot be bought. Participants are selected only against the study's eligibility criteria, and supporters have no influence over the design, the analysis or how results are reported.
When do I get access to the platform?
Early access opens to supporters at €100 and above when the beta is ready; at €50, your month of membership starts at public launch. We will keep every supporter updated on timing through the monthly progress updates.
What does “lifetime” mean?
Lifetime membership means access for as long as the platform operates. It is our commitment to the supporters who backed the work before it launched.
Is this an investment?
No. This is a founding-supporter campaign, not an offer of investment or securities. You receive rewards and early access — not equity, and not a financial return. If you would like to explore investing in the company, that is a separate conversation; please get in touch.
How are payments handled, and can I change my mind?
Payments are processed securely by Stripe; your card details never reach our servers. For the higher tiers a bank transfer is also available on request.You may withdraw within 14 days of your contribution and receive a full refund. After that period, contributions are generally non-refundable, except where required by law or where the Campaign Terms provide otherwise — including if the minimum study-funding threshold is not reached.
Will my name be published?
Only if you ask for it. Listing on the Wall of Founders is optional and you choose the name shown. You can ask to be removed at any time.
Who is behind ILT?
Integral Longevity Technologies is a Latvian company founded by Yuri Ostrinski, with co-founder Andrii Siderskyi and scientific advisor Prof. Yehuda Shoenfeld. You can read more at ilt.today.
GET INVOLVED
Join us in building the next generation of research-led Healthy Longevity solutions
Whether you are an investor, a potential partner or a future early-access user, we would be glad to meet you. Tell us a little about your interest and we will get back to you.
We use your details only to answer your enquiry. By submitting this form, you acknowledge our Privacy Notice. Please do not include medical or health information in your message.